A rare proxy fight in Germany between an activist investor and the management of Stada Arzneimittel culminated with the departure of the German generic drugmaker’s supervisory board chairman following a marathon shareholder meeting.
WSJ.com: US Business, Wall Street Journal: Business
Sat, 08/27/2016 - 3:48am
A rare proxy fight in Germany between an activist investor and the management of Stada Arzneimittel culminated with the departure of the German generic drugmaker’s supervisory board chairman following a marathon shareholder meeting.